Animal Drugs Market Size & Share 2026-2035

Animal Drugs Market Size

The global animal drugs market was valued at USD 46.3 billion in 2025. The market is expected to grow from USD 49.5 billion in 2026 to USD 82.5 billion in 2035, growing at a CAGR of 5.8% during the forecast period, as per the latest report published by Global Market Insights Inc.

The market is experiencing considerable growth driven by increasing animal population globally, high adoption of pet animals for companionship, rising cases of chronic diseases in animals, and rising expenditure on veterinary care. As per the World Animal Foundation estimates, the companion animal population reached approximately 967 million animals worldwide, of which 522 million were dogs and 445 million were cats.  According to FAO, the global ruminant livestock population is roughly 3.6 billion, of which approximately 2 billion represent livestock animals used for meat and dairy production. Similarly, the global poultry population has reached an astounding 26 billion. Such a high volume of animals increases the demand for various animal health products, including pharmaceuticals, vaccines, and feed additives, thereby boosting the market growth.
 

The animal drugs market witnessed considerable growth, growing from USD 37.7 billion in 2022 to USD 43.3 billion in 2024. This growth can be attributed to the rising prevalence of animal diseases, increasing pet ownership, and growing demand for animal-derived food products. Additionally, expanding livestock production and a greater focus on preventive veterinary care further supported market growth during this period. Furthermore, the availability of advanced medical facilities for pets, cutting-edge therapeutics, an increasing number of veterinary hospitals and clinics, and high adoption of pet insurance are further set to positively impact industry growth.
 

Also, the rising prevalence of several chronic diseases in animals, such as obesity, osteoarthritis, respiratory diseases, dental problems, diabetes, and cancer, increases the demand for drugs, further enhancing the market growth. As per the North American Veterinary Community (NAVC), diabetes is rising faster in pets than in humans, with more than half a million cats and dogs diagnosed with diabetes each year.  Further, several technological advancements in the field of veterinary medicine are set to positively influence the animal health industry. Recent developments such as telemedicine platforms and point-of-care diagnostics, coupled with ongoing research and development activities in veterinary medicine are set to bring rapid expansion in the animal drugs market.
 

Animal drugs refer to the pharmaceutical and biological products formulated to treat, prevent, or manage diseases in animals. These drugs are categorized into a broad range of products such as drugs, vaccines, and medicated feed additives. These drugs are increasingly used to treat medical conditions and help prevent the spread of infectious diseases among animals. Key market players include Boehringer Ingelheim International, Elanco Animal Health Incorporated, Merck, Zoetis, Virbac, and Ceva Sante Animale. These companies play an essential role in the market by investing in research and development, expanding product portfolios, and introducing innovative veterinary therapeutics and vaccines to address emerging animal health challenges and improve disease management across global livestock and companion animal populations.

Animal Drugs Market Trends

• The rising trend of pet humanization and increased consumer spending on pet health positively influences market growth. According to recent data, nearly 68% of households in the U.S. at present own a pet. This has created a substantial demand for pet products such as veterinary drugs. Furthermore, as owners increasingly consider pets as a part of their family, the average amount spent per household on pets is rising.
   
• For example, an average American pet owner spent USD 1,960 on their pet(s) in 2023. The average pet dog costs USD 143 per month in 2024; cat ownership costs USD 90.50 per month per cat. Thus, as households increase their spending on pets, there is a higher spending on animal pharmaceutical products, thereby fueling market growth.
   
• Further, a rise in the global demand for livestock products owing to an increase in population, rising incomes, and urbanization, has boosted the population of livestock animals. Also, the growing focus on food safety and the increasing adoption of animal-derived products expand the market potential of animal vaccines and medicated feed additives, thereby driving the market growth.
   
• Additionally, the rising incidence of chronic diseases in pets also aids in the market growth.  For instance, diabetes mellitus (DM) is a common endocrinopathy in both dogs and cats. Obesity is a significant risk factor, especially in cats. With nearly half of clinicians reporting an increase in pet obesity in the last two years, diabetes is expected to become more prevalent. Such a rise in chronic diseases increases the demand for effective treatment modalities, thereby fostering market growth.
   
• Similarly, a rise in the cases of infectious diseases in animals increases the demand for animal vaccines. For instance, in up to 99% of human rabies cases, dogs are responsible for virus transmission. Veterinary vaccines, such as the Rabies vaccine, play an important role in curbing the spread of such infectious diseases.
   
• Moreover, high adoption of pet insurance is expected to be an instrumental factor in driving the market expansion. According to the North American Pet Health Insurance Association, in 2023, the U.S. experienced 17.1% growth in total insured pets. Thus, surging demand for pet insurance, coupled with the growing number of insured animals, will drive the market expansion.
   
• Lastly, several initiatives by government and non-government bodies towards better animal welfare and safety propel the market growth. For instance, in May 2024, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) announced awards of approximately USD 22.2 million to enhance prevention, preparedness, early detection, and rapid response to the most damaging diseases that threaten U.S. livestock. Such initiatives, aimed at improving animal health, benefit the market growth.
   

Animal Drugs Market Analysis

Based on the product, the animal drugs market is segmented into drugs, vaccines, and medicated feed additives. In 2025, the drugs segment accounted for the highest market share with a revenue of USD 24.8 billion.
 

• Drugs play an essential role in treating several ailments in pets. This segment includes antiparasitic, anti-inflammatory, anti-infective drugs, and other key medications that are widely used for treating several diseases in animals.
   
• Additionally, the rising prevalence of chronic diseases in animals, coupled with growing awareness among pet owners, is increasing the adoption of veterinary pharmaceuticals, thereby boosting the segmental growth.
   
• Moreover, innovation of new drugs and therapies in veterinary medicine for companion animals has increased market growth because it expands the treatment options that can be provided.
   
• Also, the availability of advanced drug formulations and novel biologic drugs further enhances the market growth.
   
• On the other hand, the vaccines segment is anticipated to witness growth at a CAGR of 6.6% owing to the increasing focus on preventive animal healthcare, rising prevalence of infectious animal diseases, and growing government vaccination programs aimed at improving livestock health and productivity.
   

Based on indication, the animal drugs market is segmented into dermatology, cardiovascular diseases, gastrointestinal diseases, respiratory diseases, and other indications. The dermatology segment has asserted its dominance in the market by securing a significant market share of 34.1% in 2025.
 

• The dermatology segment holds a significant share in the market primarily due to the high prevalence of skin diseases among companion animals. Studies indicate that dermatological conditions account for around 20% of veterinary consultations, highlighting their high clinical burden in veterinary practice.
   
• Additionally, research shows that about 21.4% of small animal veterinary visits involve dermatological problems, while skin disorders affect around 13% of dogs and nearly 9.6% of cats under primary veterinary care.
   
• The frequent occurrence of conditions such as allergic dermatitis, parasitic infections, fungal infections, and bacterial skin diseases, along with increasing pet ownership and greater awareness of pet dermatological health, continues to drive strong demand for dermatology drugs in the animal health market.
   

Based on the animal type, the animal drugs market is classified into companion animals and livestock animals. The companion animals segment held the highest revenue in 2025 with a market share of 57.9%. The companion animals’ segment is sub-segmented into dogs, cats, horses, and other companion animals.
 

• This substantial growth is attributed to the rising adoption rate of animals such as dogs, cats, birds, and horses as pets.
   
• More than half of the global population is estimated to have a pet at home. Globally, dogs are the most popular pet, present in around one in three homes. Almost a quarter of pet owners have a cat. Thus, the sheer number of companion animals, along with increased spending, is expected to propel the segmental growth.
   
• Similarly, there has been a significant increase in the incidence of various diseases among companion animals. According to data published in the National Institute of Health (NIH), cancer is the leading cause of death in 47% of dogs, especially dogs over age ten, and 32% of cats. This rising burden of chronic diseases in pets translates to greater demand for animal drugs.
   
• Moreover, the increasing focus of manufacturers to develop and launch innovative animal drugs is set to further propel market growth.
   

Based on the route of administration, the animal drugs market is classified into oral, injectable, topical, and other routes of administration. The injectable segment dominated the market in 2025 and is anticipated to witness rapid growth at a CAGR of 5.6% over the forecast years.
 

• The injectable route involves the administration of medication via intramuscular, subcutaneous, and intravenous techniques. This method is favored due to the rapid onset of action and precise dosing, making it ideal for emergencies and acute treatments.
   
• Most vaccines, antibiotics, and analgesic medications that require quick and effective delivery of the drug are administered via the parenteral route. For example, increasing use of biologics such as monoclonal antibodies and recombinant vaccines has led to a high usage of injector devices.
   
• Moreover, innovations in injectable drug delivery by manufacturers further increase its adoption. As an example, in June 2022, NuGen Medical Devices Inc. launched the PetJet, a needle-free injector for use in pet cats and dogs. This device enables pet owners and veterinarians to conveniently administer medications without the need for needles. The PetJet allows for fast, pain-free delivery of medications, making it less stressful for pets and easier for people to administer.
   
• Lastly, the growing global burden of chronic diseases like diabetes and arthritis, which require frequent injectable drugs, is also anticipated to fuel the growth of this market.
   

Based on the distribution channel, the animal drugs market is bifurcated into veterinary hospital pharmacies, E-commerce, and retail pharmacies. In 2025, the veterinary hospital pharmacies segment dominated the market with a market share of 53.2% and is anticipated to reach USD 42.9 billion by 2035.
 

• Veterinary hospital pharmacies are dedicatedly established to dispensing medications for animals. A wide range of animal healthcare products, including prescription drugs, over-the-counter medications, vaccines, and supplements, are available in pharmacies. As they provide a comprehensive range of medications, it makes them a convenient and reliable source for purchasing animal healthcare products.
   
• Factors such as their brand recognition, high reputation for quality products, and expertise in medication dispensing are responsible for market dominance. Pet owners are more likely to trust a reputable pharmacy to purchase animal healthcare products for their animals.
   
• The e-commerce segment is expected to witness rapid growth at a CAGR of 6.7% over the forecast period. This growth can be attributed to the increasing adoption of online veterinary pharmacies, greater convenience in purchasing animal healthcare products, and improved accessibility to a wide range of veterinary drugs for pet owners and livestock farmers.
   

North America Animal Drugs Market

North America market held the largest market share of 41.6% in 2025.
 

• North America accounts for a significant share of the market, primarily driven by the high pet ownership rates, well-established veterinary healthcare infrastructure, and strong presence of leading animal health companies in the region.
   
• Additionally, increasing expenditure on companion animal healthcare, rising prevalence of animal diseases, and strong regulatory support for animal health and welfare further contribute to the region’s market dominance.
   
• The growing demand for advanced veterinary therapeutics, vaccines, and preventive care products also supports the high market share of North America.
   

The U.S. animal drugs market was valued at USD 14.5 billion and USD 15.6 billion in 2022 and 2023, respectively. The market size reached USD 17.6 billion in 2025, growing from USD 16.6 billion in 2024.
 

• According to the 2021–2022 National Pet Owners Survey by the American Pet Products Association (APPA), 70% of the U.S. households owned at least one type of pet. Additionally, almost 69 million of the U.S. households have at least one dog, and 45.3 million have at least one cat, about 9.9 million have birds, and 3.5 million have horses.
   
• Further, the country also boasts a high population of livestock animals. For instance, there were 87.2 million head of cattle and calves on the U.S. farms as of January 2024.
   
• Such a high volume of companion and livestock animals in the country increases the demand for various animal pharmaceuticals such as drugs, vaccines, and medicated feed additives, thus boosting the growth of the U.S. market.
   

Europe Animal Drugs Market

Europe market accounted for USD 12.9 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Rising animal adoption in European region, coupled with increasing initiatives by the government to improve animal healthcare, is anticipated to spur the market growth.
   
• Moreover, advancements in veterinary medicine with frequent introduction and approval of novel pharmaceuticals will boost the market in the Europe region.
   
• Also, the presence of highly equipped veterinary clinics and hospitals in Germany, UK, and France, further boosts the Europe market.
   

Germany animal drugs market is anticipated to witness significant growth in the coming years.
 

• As of 2023, 45% of German households have a pet, and 14% of households have two pets or more. This totals approximately 34.3 million pets. Cats and dogs are the most popular house pets, with 25% of German households owning cats and 21% of households owning dogs.
   
• The rising adoption of pet animals, coupled with surging expenditure on veterinary care, is set to augment the market size in Germany.
   
• Moreover, a large livestock population in the country drives the demand for various vaccines and feed additives. In 2024, the cattle population in Germany was 10.63 million.
   
• Favorable laws and policies implemented in the region by regulatory authorities further aid in the growth of companies operating in the market.
   

Asia Pacific Animal Drugs Market

The Asia Pacific animal drugs market demonstrates significant growth potential.
 

• The market in the Asia Pacific region is growing rapidly due to the rise in pet ownership, advancements in animal health awareness, and the improvement of veterinary care infrastructure.
   
• Additionally, a rise in the number of veterinary clinics and hospitals, coupled with government policies aimed at animal health care contribute to the rapid growth of the market in the region.
   
• Moreover, the presence of both international market players and local regional manufacturers intensifies the market competition, further driving the regional market growth.
   

India animal drugs market is poised to witness high growth over the analysis period.

• India has a large pet population with over 31 million pet dogs and 2.44 million pet cats. The increasing pet ownership and rising disposable income in the country, coupled with high expenditure on pet healthcare, will offer lucrative market growth opportunities in the country.
   
• In addition, the rapidly expanding veterinary infrastructure in the country, such as veterinary hospitals and clinics, will further enhance the market growth.
   
• Furthermore, several government initiatives to support animal health and wellness also stimulate the market growth. For instance, the National Animal Disease Control Programme is a flagship scheme launched in 2019 that aims to control foot and mouth disease and brucellosis by vaccinating the animals. Such initiatives aid in high adoption of animal pharmaceuticals and vaccines, thus fostering the market growth.
   

Latin America Animal Drugs Market

Brazil market is anticipated to witness rapid growth over the forecast years.
 

• Brazil has the third-largest pet population in the world, with 160 million pets, of which 60 million are dogs, 30 million cats, and 32 million pet-owning households. The country is also home to a large livestock population, with Brazil being the third-largest cattle producer and second-largest beef exporter in the world. Such high animal volume, coupled with strong growth in veterinary expenditure, is anticipated to foster the market growth.
   
• Additionally, the presence of several international as well as local veterinary companies in the country further aid in the market growth.
   

Middle East & Africa Animal Drugs Market
 

Saudi Arabia market is set for lucrative growth in the Middle East and Africa market.
 

• The increasing pet ownership in the country, rising disposable income, coupled with a rapidly expanding veterinary infrastructure, will offer lucrative market growth opportunities in the country.
   
• One of the factors supporting the growing trend of acquiring and caring for pets in Saudi Arabia is the notable increase in the number of veterinary clinics. As per data published by GlobalPETS, currently, there are 434 clinics, and the number of specialized veterinary pharmacies has increased to 1366, catering specifically to the needs of pets.
   
• In addition, rising government initiatives to boost animal welfare and support businesses in the veterinary industry aid in the market growth.
   

Animal Drugs Market Share

The market is highly competitive, with several key companies striving to develop novel formulations in the market. The market is fragmented in nature, with major organizations, local small players, and start-ups joining the industry competition. The top 5 companies in the market, such as Zoetis, Elanco Animal Health, Merck & Co., Inc., Virbac, and Boehringer Ingelheim International, account for approximately 54.8% of the global market share.
 

Additionally, there are several local and regional players operating in the market that are boosting competition by providing affordable options at lower costs. These players are also involved in several strategies, such as mergers, acquisitions, and novel product launches, to expand their product offerings. For instance, in February 2021, Vetoquinol announced the acquisition of the Canadian rights to the Profender product family from Elanco Animal Health. The Profender range consists of spot-on de-wormer products for cats. Such initiatives by market players enhance the competitive landscape in the market, thereby boosting the market growth.
 

Animal Drugs Market Companies

Prominent players operating in the animal drugs industry include:

• Agrolabo S.p.A.
• Boehringer Ingelheim International
• Ceva Santé Animale
• Chanelle Pharma
• Dechra Pharmaceuticals
• Durvet Animal Health Products
• Elanco Animal Health
• Endovac Animal Health
• HIPRA
• Indian Immunologicals
• Merck & Co., Inc
• Neogen Corporation
• Norbrook
• Vetoquinol
• Virbac
• Zagro
• Zoetis

 

• Zoetis

Zoetis is one of the leading global animal health companies with a market share of ~19.1%. The company discovers, develops, manufactures, and commercializes a diverse portfolio of animal health medicines and vaccines and has operations in over 100 countries. The company's dedication to R&D stimulates innovation in animal healthcare, allowing the launch of novel, effective, and safe treatments.
 

• Boehringer Ingelheim International

Boehringer Ingelheim has a notable presence in the market. The company offers a wide array of products, including vaccines, anti-infectives, parasiticides, and therapeutic solutions designed to improve animal health. NexGard SPECTRA is a chewable product designed for dogs. This product leverages the rising trend of pet ownership and increasing awareness about pet health and wellness in India. This strategy is expected to add value to the company’s business portfolio.
 

Animal Drugs Industry News

• In January 2025, Ceva Sante Animale and Touchlight signed an agreement to use dbDNA technology to develop and manufacture products across the animal health sector. Through this, the company strengthens its product portfolio and leverages advanced technologies.
   
• In September 2024, Boehringer Ingelheim acquired Saiba Animal Health, focused on the development of drugs for pets to manage chronic diseases. This strategic acquisition helped the company to broaden its product portfolio and strengthen its animal health R&D pipeline.
   
• In September 2024, Elanco Animal Health announced the approval of Zenrelia for controlling pruritus (itching) associated with allergic dermatitis and atopic dermatitis in dogs. This launch facilitated the company to boost revenue growth by adding a new product.
   
• In June 2024, Merck Animal Health received approval for NOBIVAC NXT Canine Flu H3N2 by the USDA which is the first and only RNA-particle technology vaccine for treating dogs with influenza. This product approval has helped the company broaden its offerings and enhance its position in the market.
   
• In April 2024, Virbac acquired Sasaeah animal health subsidiary of ORIX Corporation. This strategic acquisition will give Virbac a leadership position in the animal vaccines market in Japan. This strategic move is expected to secure Virbac a controlling position in the Japanese animal vaccines market, enhancing its competitive edge and expanding its footprint in the region.
   

The animal drugs market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Market, By Product

• Drugs
  • Antiparasitic
  • Anti-inflammatory
  • Anti-infectives
  • Corticosteroids
  • Tranquilizers
  • Cardiovascular drugs
  • Gastrointestinal drugs
  • Other drugs
• Vaccines
  • Modified live vaccines (MLV)
  • Killed inactivated vaccines
  • Recombinant vaccines
• Medicated feed additives
  • Antibiotics
  • Vitamins
  • Amino acids
  • Enzymes
  • Antioxidants
  • Prebiotics and probiotics
  • Minerals
  • Other medicated feed additives

Market, By Indication

• Dermatology
• Cardiovascular diseases
• Gastrointestinal diseases
• Respiratory diseases
• Other indications

Market, By Animal Type

• Companion animals
  • Dogs
  • Cats
  • Horses
  • Other companion animals
• Livestock animals
  • Poultry
  • Swine
  • Cattle
  • Fish
  • Other livestock animals

Market, By Route of Administration

• Oral
• Injectable
• Topical
• Other routes of administration

Market, By Distribution Channel

• Veterinary hospital pharmacies
• E-commerce
• Retail pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Taiwan
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • GCC countries
  • Israel